TerminatedPhase 2NCT01861301
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Hedy KindlerUniversity of Chicago Comprehensive Cancer Center
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2015
Study locations (18)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- City of Hope South Pasadena, South Pasadena, California, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Illinois CancerCare-Peoria, Peoria, Illinois, United States
- Southern Illinois University School of Medicine, Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01861301 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited